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stratiﬁed our analysis among patients with 2 or more risk factors,
and found that 72% returned to see the physician within the
intervention group compared to 59 % of the control group
(p-value < 0.05). The intervention also produced a signiﬁcant
increase in the percentage of patients who reported they were
conﬁdent about lowering stroke risk with the physician assis-
tance (69% versus 52%, p-value < 0.05). After confounder
adjustment, patients in the intervention group were still 1.8 times
more likely to visit their physicians than patients in the control
group, in multivariate analyses (p < 0.05). CONCLUSION: This
randomized controlled trial illustrates that provision of tele-
phonic intervention is effective in increasing patient visits to the
physician after stroke screening. These results can be used to
maximize the clinical utility of risk factor identiﬁcation in high
risk communities.
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OBJECTIVE: The 14-item Treatment Satisfaction Questionnaire
for Medication Version I (TSQM) is a reliable and valid instru-
ment to assess patients’ satisfaction with medication, providing
scores on four scales—side effects, effectiveness, convenience and
global satisfaction. In naturalistic studies, using the TSQM with
the side effects domain has a potential to interfere with routine
medical care. In this study, an interactive voice response system
(IVRS)-administered abbreviated 9-item TSQM without the ﬁve
items of the side effects domain (TSQM-9) was psychometrically
evaluated among patients taking antihypertensive medication.
METHODS: A total of 396 subjects who self-reported taking a
prescribed antihypertensive medication were recruited from an
online panel. The subjects were asked to complete the TSQM-9
at the start of the study, along with the modiﬁed Morisky scale,
and then again within 7 to 14 days. Psychometric analyses
including conﬁrmatory factor analysis (CFA), Cronbach’s
alpha and intraclass correlation coefﬁcients were conducted.
RESULTS: There was evidence of construct validity of the
TSQM-9 based on the CFA ﬁndings of the observed data
ﬁtting the Decision Balance Model of Treatment Satisfac-
tion even without the side effects domain (Non-normed Fit
Index = 0.9791; Bentler’s Comparative Fit Index = 0.9860).
TSQM-9 domains had good internal consistency as evident from
Cronbach’s alpha values of 0.84 and greater. TSQM-9 domains
also demonstrated good test-retest reliability with high intraclass
correlation coefﬁcients exceeding 0.70. As expected, the
TSQM-9 domains were able to differentiate between individuals
who were high compliers with medication use and those that
were low compliers, with a moderate-to-high effect size (Cohen’s
d ranging from 0.6 to 0.8). There was evidence of convergent
validity with signiﬁcant correlations with the medication adher-
ence scale. CONCLUSION: The IVRS-administered TSQM-9
was found to be a reliable and valid measure to assess treatment
satisfaction in naturalistic study designs, in which there is poten-
tial for the TSQM’s side effects domain to interfere with routine
clinical care.
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OBJECTIVE: To measure the impact of patient targeted educa-
tion designed to inform atorvastatin users of lower cost anti-
hyperlipidemic alternatives after atorvastatin was removed
from their formulary. METHODS: A retrospective case-control
research design was used with case and control groups composed
of clients that implemented the formulary change on January 1,
2006 and had ﬂat 3-tier copayments. Case group members were
enrolled in clients that implemented a targeted communication
strategy and control group members did not. Success was mea-
sured as switching to a formulary antihyperlipidemic on or after
June 30, 2006. Logistic regression models, estimated separately
for retail and home delivery (HD) channels, was used to estimate
the impact of education on the likelihood of switching control-
ling for age, gender, high dose (40 or 80 MG), prior switching,
household median income, non-preferred and generic copayment
differential, and other client-level trend programs (i.e., step
therapy). RESULTS: A total of 201,223 patients in the control
group and 165,758 patients in the case group met the study
inclusion criteria. Controlling for patient and plan covariates,
patients in the case group in retail were 3.48 times more likely
to switch to a preferred statin (95% Conﬁdence Interval
(CI) = 3.38–3.59) compared to control group members. In HD,
the likelihood of switching was 9.82 (95% CI = 9.46–10.20).
This translates into an absolute increase in the switch rates of
14.3 and 29.8 percentage points for patients in retail and HD,
respectively. CONCLUSION: In the context of a formulary
change, targeted member communication and assistance is an
effective means of promoting lower cost formulary alternatives.
Greater conversion in HD may be related to a higher degree of
assistance and outreach within this channel.
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OBJECTIVE: To assess the clinical effectiveness and cost-
effectiveness of low-density-lipoprotein (LDL) apheresis for
treatment of patients with homozygous (HMZ) and heterozy-
gous (HTZ) familial hypercholesterolemia (FH). METHODS:
Seven case series and one retrospective review with heparin-
induced extracorporeal LDL precipitation (HELP) for the treat-
ment of refractory HMZ and HTZ FH published between
January 1998 and May 2007 were included in the analysis.
RESULTS: The mean acute decrease in LDL-C ranged from
53–77% with HELP. The mean chronic decrease in LDL-C
ranged from 9–46% and the increase in HDL-C ranged from
12–27%. The LDL:HDL ratio exceeded target values. There was
a beneﬁcial impact on coronary outcomes demonstrated by a
decrease in Agatston scores and a regression in atherosclerotic
lesions. Adverse events, ranging 2.9–5.1%, were typically mild
and related to vascular access problems. Studies were generally of
low quality however performing controlled studies is not feasible
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given that HELP represents a last therapeutic option for these
patients. The annual budget impact was $1.0 and $61.0 million
(CAD) for HMZ and HTZ FH patients respectively. Costs were
halved with biweekly treatment. The cost per CHD death
avoided comparing HELP with Plasma Exchange (PE), current
treatment, and with no intervention in HTZ FH was estimated to
be $37.5 million and $18.7 million for weekly and biweekly
treatment respectively. Although HELP costs twice as much as
PE, it avoided 12 deaths versus PE and 22 deaths versus no
intervention over a 10-year period. CONCLUSION: There is
evidence of overall clinical beneﬁt of LDL apheresis for HMZ
and HTZ FH. The diffusion of LDL apheresis for refractory HTZ
FH should factor affordability and potential capital and human
resource constraints.
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OBJECTIVE: Point-of-Care (POC) devices that measure the
International Normalized Ratio (INR) may be associated with
enough measurement error to inﬂuence warfarin dosing deci-
sions. The purpose of this trial was to determine if there were
differences between any of ﬁve FDA-approved POC testing
devices in terms of the proportion of time patients spend in the
target INR range (TR). METHODS: In this longitudinal clinical
trial, patients were randomized to one of ﬁve POC devices that
measure the INR (International Normalized Ratio). Patients
were followed over time according to usual anticoagulation clinic
practice. Clinicians used measurements from the POC device to
make all clinical decisions, including warfarin dose changes. At
each visit, a venous blood sample was also collected to serve as
an accepted standard measure to calculate time in the target
range (TR). A Bayesian hierarchical model with a parametric
variance component for estimating coagulation times between
observed blood draws was used to estimate the mean proportion
of time each patient’s INR was within his or her TR. The analysis
assessed the probability that each device resulted in patients’ INR
values within the TR over time, as measured by the accepted
standard laboratory measure. RESULTS: A total of 287 patients
were enrolled, completed 3 visits, and were monitored for an
average of 87 days. There was signiﬁcant differences in the time
patients’ INR values were in the target range, based on POC
device: Coaguchek S (52.2%), Coaguchek ProDM (51.5%)
Hemochron Jr. (48.3%), ProTime (45.5%), and Rapidpoint
(41.2%). The posterior probabilities that the Coaguchek S and
Coaguchek ProDM were the superior devices were 0.58 and
0.31, respectively. CONCLUSION: Five FDA-approved POC
INR devices resulted in signiﬁcantly different time in the TR. This
suggests that there are clinically signiﬁcant differences amongst
FDA-approved devices. Measurement of clinical outcomes may
improve the regulatory approval process.
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OBJECTIVE: Evaluate treatment patterns and levels of blood
pressure (BP) and glycemic control in elderly patients with
comorbid hypertension and type 2 diabetes. METHODS: Retro-
spective review of 2 consecutive years (August 1, 2005–July 31,
2007) of medical claims, pharmacy claims, and medical charts
from a physician group, comprised of more than 200 physicians,
located in the Ohio Valley region. Patients 65 years-of-age and
older with an ICD-9 diagnosis code for both hypertension and
type 2 diabetes were identiﬁed for inclusion between August 1,
2005–July 31, 2006, and evaluated from August 1, 2006–July
31, 2007. Administrative claims databases were utilized to
analyze treatment patterns. Medical charts was reviewed to
conﬁrm diagnoses and collect clinical indicators of control,
including BP and hemoglobin A1C measurements. RESULTS:
This study included 505 patients with hypertension and type 2
diabetes. The mean age was 75.7 years, and 57% were females.
Approximately 35% (n = 177) achieved BP goal of <130/
80 mmHg, while 58% (n = 293) achieved glycemic control,
deﬁned as A1C <7%. Only 26% (n = 133) attained both goal BP
and A1C levels. The most prescribed antihypertensive and anti-
hyperglycemic classes were beta-blockers (50%) and sulfony-
lureas (44%), respectively. Forty-seven percent of the patients
were on an angiotensin converting enzyme inhibitor, and 14%
were on an angiotensin receptor blocker. Antihypertensive mono-
therapy was the least prevalent (21%) mode of therapy, followed
by therapy with two agents (29%), and >3 agents (50%). In
contrast, antthyperglycemic monotherapy was the most preva-
lent (55%) mode of therapy, followed by dual therapy (30%),
and >3 agents (15%). CONCLUSION: Elderly patients with
comorbid hypertension and type 2 diabetes did not achieve goal
BP, and over 40% did not achieve goal A1C. Further opportu-
nities to educate both health care providers and patients are
necessary in order to prevent complications associated with the
poor management of these two common conditions.
PCV78
INTERNATIONAL COMPARISON OF HEALTH CARE
RESOURCES AND QUALITY OF LIFE IN ACUTE CORONARY
SYNDROME PATIENTS IN 2007: RESULTS FROMTHE
ANTIPLATELETTREATMENT OBSERVATIONAL STUDY
(APTOR)
Bakhai A1, Iniguez A2, Ferrieres J3, Needs N4, Schmitt C4, Sartral M5,
Zeymer U6
1Barnet & Chase Farm NHS Trust, Barnet, UK, 2Hospital Meixoeiro,
Vigo, Spain, 3CHU Rangueil, 31059 Toulouse, France, 4Eli Lilly and
Company Ltd,Windlesham, Surrey, UK, 5Eli Lilly and Company Ltd,
Suregnes, Paris, France, 6Institute for MI Research, Ludwigshafen,
Germany
OBJECTIVE: To explore variation in practice and its impact on
QoL in management of acute coronary syndromes (ACS), the
commonest cardiac cause of hospital admission. METHODS: A
prospective, international, observational study recruited ACS
patients undergoing percutaneous coronary intervention (PCI),
January–August 2007, capturing practice patterns, resource use
and QoL. RESULTS: A total of 1525 ACS-PCI patients (Spain-
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